Page last updated: 2024-08-26

sr141716 and Hyperlipemia

sr141716 has been researched along with Hyperlipemia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, W; Chen, Z; Li, S; Wang, L; Xue, N; Zheng, Z1
Ducobu, J1
Tonstad, S1
Bodary, PF; Eitzman, DT; Iglay, HB1

Reviews

2 review(s) available for sr141716 and Hyperlipemia

ArticleYear
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2

    Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain

2006
Strategies to reduce vascular risk associated with obesity.
    Current vascular pharmacology, 2007, Volume: 5, Issue:4

    Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors

2007

Other Studies

2 other study(ies) available for sr141716 and Hyperlipemia

ArticleYear
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:8

    Topics: Adipose Tissue; Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Glucose Intolerance; Hyperlipidemias; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Insulin; Rimonabant; Sodium Glutamate

2013
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
    Revue medicale de Bruxelles, 2005, Volume: 26, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Piperidines; Pyrazoles; Rimonabant

2005